ETC-1002 – 5 mg

Brand:
Cayman
CAS:
738606-46-7
Storage:
-20
UN-No:
Non-Hazardous - /

ETC-1002 is a prodrug form of ETC-1002-CoA.{46141} ETC-1002 is conjugated to coenzyme A (CoA) by very long-chain acyl-CoA synthetase-1 (ACSVL1) to form ETC-1002-CoA, which inhibits ATP citrate lyase (Ki = 2 μM) and activates AMP-activated protein kinase (AMPK). ETC-1002 suppresses total lipid synthesis in wild-type and AMPKβ1 knockout primary murine hepatocytes. In vivo, ETC-1002 (30 mg/kg) prevents increases in hepatic cholesterol and reduces the size of aortic atherosclerotic lesions induced by a high-fat high-cholesterol diet in Apoe-/-/Ampkβ1-/- (DKO) mice.  

 

Available on backorder

SKU: 26409 - 5 mg Category:

Description

A prodrug form of ETC-1002-CoA; conjugated to CoA by ACSVL1 to form ETC-1002-CoA, which inhibits ATP citrate lyase (Ki = 2 μM) and activates AMPK; suppresses total lipid synthesis in wild-type and AMPKβ1 knockout primary murine hepatocytes; prevents increases in hepatic cholesterol and reduces the size of aortic atherosclerotic lesions induced by a high-fat high-cholesterol diet in DKO mice,


Formal name: 8-hydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid

Synonyms:  Bempedoic Acid|ESP-55016

Molecular weight: 344.5

CAS: 738606-46-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Activators|Kinases||Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Lipids & Lipoproteins